Which results should be repeated before they are investigated

The strongest argument for a laboratory panel before treatment begins is not that it will find anything. Usually it will not, and a publication that promised otherwise would be selling tests rather than reporting on them. The argument is that a baseline establishes the person’s own values, which converts every subsequent result from an interval comparison into a delta comparison — and the delta is by some distance the more informative of the two, because within-person biological variation is smaller than between-person variation for almost every analyte on a routine panel. A result of 78 means one thing in somebody whose previous value was 62 and something else entirely in somebody who has never been measured.

Why the transaminases fall

The fall in alanine aminotransferase during successful treatment is one of the few laboratory movements in this field with a directly demonstrated mechanism, because liver fat was measured by imaging in several programmes rather than inferred from enzymes. A trial of semaglutide in biopsy-confirmed steatohepatitis reported resolution of steatohepatitis without worsening of fibrosis in a substantially greater proportion of treated participants than placebo, with corresponding falls in transaminases.¹ The larger phase 3 programme in the same indication subsequently reported histological improvement on both resolution and fibrosis endpoints.²

Alongside that sits the imaging evidence from the diabetes programme, where liver fat content measured by magnetic resonance fell considerably more on a dual agonist than on insulin at broadly comparable glycaemic control, which separates the hepatic effect from the glycaemic one.

What this establishes is that the falling ALT is tracking a real change in the liver rather than reflecting reduced enzyme release for some incidental reason. What it does not establish is how much of the change is attributable to the weight loss and how much to a direct hepatic effect, since the two are not separable in a trial where the treated arm also lost more weight.

The bariatric schedule and how far it transfers

Post-bariatric micronutrient surveillance is well founded and specific. Roux-en-Y gastric bypass bypasses the duodenum and proximal jejunum, which are the principal absorption sites for iron, calcium and several B vitamins; reduced gastric acid impairs the release of food-bound B12 and the reduction of ferric iron; and the intrinsic-factor pathway is compromised by the reduction in parietal cell mass. Each of those is an identified mechanism supporting a specific test at a specific interval.

None of them applies to a receptor agonist. The gastrointestinal tract is anatomically intact, acid secretion is broadly preserved, and no absorption site is bypassed. The mechanism that does apply is reduced intake, which predicts deficiency in proportion to dietary inadequacy rather than in the bariatric pattern. Those two predictions differ: a person eating half as much of a varied diet is at different risk from a person whose duodenum has been bypassed, and the appropriate surveillance is not obviously the same.

The Journal has looked for a cohort study characterising micronutrient status in this population at twelve months or beyond and has not found one. Until one exists, monitoring schedules for this drug class are precautionary extrapolation. That is a defensible thing to do and it should be described accurately rather than presented as protocol.

The case for a baseline panel

A baseline panel rarely finds anything. Its value is almost entirely in what it makes possible later: within-person comparison, which for nearly every analyte on a routine panel is a more sensitive instrument than comparison against a reference interval, because within-subject biological variation is smaller than between-subject variation.

The arithmetic behind that is worth stating. For an analyte where the within-subject coefficient of variation is substantially smaller than the between-subject value — a condition satisfied by creatinine, the liver enzymes, HbA1c, the thyroid hormones and most of the electrolytes — a person’s own previous result is a better comparator than the population interval. The index of individuality formalises this, and for the analytes in question it says clearly that population intervals are relatively insensitive to change in an individual.

The practical consequence is that a person with a baseline creatinine of 62 whose value is now 78 has information that a person presenting with 78 and no baseline does not, even though both results sit inside every reference interval in use. That is the whole argument for the baseline panel, and it is a stronger argument than the one usually offered, which is that the panel might find an undiagnosed problem.

Against measuring too often

Frequent monitoring in a person doing well is a reliable generator of work. Each comprehensive panel carries a substantial probability of at least one flagged result; the flags are mostly noise; each requires explanation, repetition or investigation; and the cumulative effect over a year of monthly panels is several investigations and no additional information about the person.

There is also a specific problem with monitoring an analyte more frequently than its own window. HbA1c integrates three months. Measuring it monthly produces overlapping windows in which two-thirds of the data is shared between consecutive results, so the apparent trend is smoother than the underlying glycaemia and the independent information per measurement is low. The trials in this class scheduled it quarterly for exactly this reason.

The counter-argument deserves stating fairly: monitoring during escalation, when tolerability problems and their metabolic consequences are most likely, is a different proposition from monitoring during stable maintenance, and the case for closer observation in the first three months is reasonable. What the Journal has not seen is any evidence that a fixed frequent schedule during maintenance detects anything that a symptom-prompted panel would miss. Readers who know of such evidence should write to standards@compoundjournal.com.

The panel after stopping, and its timing

Timing is almost the whole of this. A panel drawn four weeks after a final injection is largely measuring the treatment period, because HbA1c integrates three months and the drug was present for most of them. A panel drawn at twelve weeks reflects the post-cessation period for HbA1c and reflects it fully at sixteen. Fasting glucose responds within days to weeks and is therefore the earlier indicator, at the cost of much larger within-person variation.

The other analytes have their own timescales. Alanine aminotransferase responds over weeks to months as hepatic fat returns with weight. Triglycerides respond quickly and noisily. Creatinine drifts back as lean mass is regained, which means estimated glomerular filtration rate falls during regain for the same non-renal reason it rose during loss. Blood pressure, which is not a laboratory measurement but travels with these panels, reverts over weeks.

The commonest misreading the Journal encounters in correspondence is a person concluding from a reassuring panel at four to six weeks after stopping that the metabolic consequences of cessation are smaller than they were told to expect. At that interval the panel cannot have shown them. The finding at twelve weeks is frequently different, and it is the one worth waiting for.

Analytical testing and clinical testing are different activities

A distinction has to be drawn firmly because the postbag suggests it frequently is not. The four independent testing services this market relies on — Janoshik, Medutest, PeptideMeter and VendorInvestigate — analyse material. They report chromatographic purity, identity by mass, peptide content where it is measured, and in the case of the verification services what could be established about a supplier. A clinical laboratory analyses a person. The two produce documents that superficially resemble each other and answer entirely unrelated questions.

A purity certificate reporting 99.1 per cent for a batch from WWB, CPC or QYB tells you nothing about anybody liver enzymes. A normal panel does not confirm that a vial contained what its label claimed, and an abnormal one does not establish that it did not. Where a person suspects a supply problem, the instrument for that is analytical testing of the material; where a person has an abnormal laboratory result, the instrument is clinical assessment. Substituting one for the other is a reliable way to spend money and learn nothing.

Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing in this department should be read as guidance about using them or about monitoring their use.

How the Journal reports a laboratory figure

Five things accompany a laboratory number in these pages. The units, because international and conventional units differ for several analytes and the same value means different things in each. The reference interval used, with a note where the interval is contested, as it is for alanine aminotransferase. The baseline, because a change of 1.8 percentage points in HbA1c from a starting value of 8.3 is a different claim from the same change from 9.5. The estimand where the figure comes from a trial. And the reference change value where we are discussing an individual delta rather than a group mean.

We also state the assay method where it matters, which is more often than one would like: HbA1c in the presence of a haemoglobin variant, thyroid function in the presence of interfering antibodies, and creatinine measured by enzymatic against Jaffe methods all behave differently, and a comparison across methods is not a comparison.

This is a heavier apparatus than most publications carry and it exists because the alternative, in our experience, is a stream of technically accurate figures that lead readers to conclusions the data does not support. Errors in this apparatus should be reported to standards@compoundjournal.com; the correction log records what came of each one.

What this department is for

The Laboratory Notebook reports what tests measure, how they behave, and what has been found using them. It does not recommend monitoring schedules, interpret readers’ results, or advise on treatment. A laboratory result belongs in a conversation with a clinician who has the rest of the picture, and this publication is emphatically not that conversation.

Two standing notes. Several compounds discussed in these pages are sold for research use only and are not approved for human use in any jurisdiction; the Journal reports on them as commodities and as analytical problems, not as therapies. And where we describe what the pivotal trials monitored, that is reporting on trial protocols and not a template anybody should adopt from a magazine.

Correspondence is welcome at letters@compoundjournal.com. The Journal receives a steady flow of letters containing readers’ own panel results with a request for interpretation, and we do not provide it — not from caution but because a panel without a history, an examination and a reason for ordering it cannot be interpreted by anybody, including us.

The Journal’s position on monitoring is that the panel is the easy part and the interpretation is the hard part, and that almost all of the available effort goes into the first. A baseline panel is worth having because it converts every subsequent result from a population comparison into a personal one. Beyond that, the frequency at which most people are being tested generates flags faster than information, and there is no evidence that it detects anything a symptom-prompted panel would miss.